Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid

Cancer Research

Volumn 71, Issue 12, 2011, Pages 4150-4160

  Roos, Wynand P ^a   Jöst, Eva ^a   Belohlavek, Christina ^a   Nagel, Georg ^a   Fritz, Gerhard ^a   Kaina, Bernd ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BETA1A INTERFERON; CASPASE 3; CASPASE 7; DACARBAZINE; DEATH RECEPTOR; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; HISTONE H2AX; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; RECOMBINANT ALPHA2A INTERFERON; SMALL INTERFERING RNA; TEMOZOLOMIDE; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA ALKYLATION; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG SENSITIZATION; ENZYME ACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERFERON-BETA; MALE; MELANOMA; MICE; TUMOR SUPPRESSOR PROTEINS; VALPROIC ACID;

EID: 79958803363     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3498     Document Type: Article

References (48)

1. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010;46:270-83.
2. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001-7. (Pubitemid 46211484)
3. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 2003;13:303-6. (Pubitemid 36683775)
4. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78:1199-202. (Pubitemid 28479151)
5. Ridolfi R, Romanini A, Sileni VC, Michiara M, Guida M, Biasco G, et al. Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Res 2004; 14:295-9. (Pubitemid 39159143)
6. Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, et al. Lowdose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 2005;23:8992-9000. (Pubitemid 46211483)
7. Beranek DT. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 1990;231: 11-30. (Pubitemid 20195889)
8. Dianov GL, Souza-Pinto N, Nyaga SG, Thybo T, Stevnsner T, Bohr VA. Base excision repair in nuclear and mitochondrial DNA. Prog Nucleic Acid Res Mol Biol 2001;68:285-97. (Pubitemid 33804669)
9. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
10. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6:1079-99. (Pubitemid 47058389)
11. Kaina B, Fritz G, Mitra S, Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991;12: 1857-67.
12. Margison GP, Santibanez-Koref MF. O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002;24:255-66. (Pubitemid 34248691)
13. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide- induced DNA lesion O6-methylguanine. Oncogene 2007;26: 186-97. (Pubitemid 46095730)
14. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A 1999;96:10764-9. (Pubitemid 29442218)
15. Loechler EL, Green CL, Essigmann JM. In vivo mutagenesis by O6-methylguanine built into a unique site in a viral genome. Proc Natl Acad Sci U S A 1984;81:6271-5.
16. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 2004;3:1091-101. (Pubitemid 38997952)
17. Dosch J, Christmann M, Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 1998;19:567-73. (Pubitemid 28376798)
18. Karran P, Stephenson C. Mismatch binding proteins and tolerance to alkylating agents in human cells. Mutat Res 1990;236:269-75. (Pubitemid 20309365)
19. Mojas N, Lopes M, Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent singlestranded gaps in newly replicated DNA. Genes Dev 2007;21: 3342-55. (Pubitemid 350277760)
20. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000;60:5815-24.
21. Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 2009;8:72-86.
22. Isaacs A, Lindenmann J. Virus interference.I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
23. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67: 227-64. (Pubitemid 28411130)
24. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997;17:355-67. (Pubitemid 27260291)
25. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002;169:847-55. (Pubitemid 34753441)
26. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009;100:322-33.
27. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007;67:2632-42. (Pubitemid 46548950)
28. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387-95. (Pubitemid 36693759)
29. Pegg AE, Boosalis M, Samson L, Moschel RC, Byers TL, Swenn K, et al. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry 1993;32: 11998-2006. (Pubitemid 23353637)
30. Roos W, Baumgartner M, Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004;23:359-67. (Pubitemid 38174989)
31. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007;67: 11886-95.
32. Tewari M, Dixit VM. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 1995;270:3255-60.
33. Ehrhardt H, Hacker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, et al. Cytotoxic drug-induced, p53-mediated upregulation of caspase- 8 in tumor cells. Oncogene 2008;27:783-93. (Pubitemid 351186307)
34. Preuss I, Eberhagen I, Haas S, Eibl RH, Kaufmann M, von Minckwitz G, et al. O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 1995;61:321-6.
35. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188: 2033-45. (Pubitemid 28562520)
36. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-76.
37. Haapajarvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF, et al. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Exp Cell Res 1999;248:272-9.
38. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994;4:35-45. (Pubitemid 24127098)
39. Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, Seizinger BR, et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993; 55:562-5. (Pubitemid 23328938)
40. Lubbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutations in cutaneous melanoma. J Invest Dermatol 1994;102: 819-21. (Pubitemid 24144269)
41. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12:440-50. (Pubitemid 44291571)
42. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000;19:4604-10.
43. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77. (Pubitemid 32937956)
44. Liedtke C, Groger N, Manns MP, Trautwein C. Interferon-alpha enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells. J Hepatol 2006;44:342-9. (Pubitemid 43069216)
45. Kim KB, Choi YH, Kim IK, Chung CW, Kim BJ, Park YM, et al. Potentiation of Fas- and TRAIL-mediated apoptosis by IFN-gamma in A549 lung epithelial cells: enhancement of caspase-8 expression through IFN-response element. Cytokine 2002;20:283-8. (Pubitemid 36299048)
46. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005;19:1751-9. (Pubitemid 41486152)
47. Kaina B, Margison GP, Christmann M. Targeting O-methylguanine- DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 2010;67:3663-81.
48. Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, et al. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer 2009;100:1250-6.